Terms: = Prostate cancer AND GATA3, HDR, 2625, ENSG00000107485, MGC5445, MGC5199, MGC2346 AND Prognosis
16 results:
1. Primary mucinous adenocarcinoma of the urethra: A contemporary clinicopathologic analysis of 17 patients.
Alrohaibani A; Osunkoya AO
Pathol Res Pract; 2024 Apr; 256():155273. PubMed ID: 38565023
[TBL] [Abstract] [Full Text] [Related]
2. Clear cell urothelial carcinoma of bladder: Case report of a rare and aggressive variant with review of literature.
Sahetia KM; Dave VN; Pal M; Menon S
Indian J Cancer; 2023 Oct; 60(4):575-577. PubMed ID: 38145907
[TBL] [Abstract] [Full Text] [Related]
3. Characteristics and survival of primary urothelial carcinoma of the prostate: A multi-center retrospective study of 18 cases.
Ji J; Liu T; Yao Y; Liu W; Ning H; Wang T; Zhang G
Neoplasia; 2024 Jan; 47():100961. PubMed ID: 38142529
[TBL] [Abstract] [Full Text] [Related]
4. [Clinicopathological Features of Primary Small Cell Neuroendocrine Carcinoma of the Bladder].
Gu YM; Liang XL; Zhang YG; Zhao HY; Jin ML; Li X; Lu J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Jun; 45(3):429-435. PubMed ID: 37407530
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of outcomes in high-risk prostate cancer patients treated with low-/high-dose-rate brachytherapy plus external beam radiotherapy.
Imai Y; Urabe F; Iwatani K; Nakazono M; Tashiro K; Honda M; Aoki M; Sato S; Takahashi H; Miki K; Kimura T
Int J Clin Oncol; 2023 May; 28(5):698-706. PubMed ID: 36814038
[TBL] [Abstract] [Full Text] [Related]
6. Extramammary Paget Disease of the Scrotum: A Contemporary Clinicopathologic Analysis of 20 Cases in the United States.
Shabihkhani M; Patil P; Murati Amador B; Plaza JA; Osunkoya AO; Lombardo KA; Epstein JI; Matoso A
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):524-531. PubMed ID: 31290785
[TBL] [Abstract] [Full Text] [Related]
7. Good prognosis following a PSA bounce after high dose rate brachytherapy and external radiotherapy in prostate cancer.
Åström L; Sandin F; Holmberg L
Radiother Oncol; 2018 Dec; 129(3):561-566. PubMed ID: 30193693
[TBL] [Abstract] [Full Text] [Related]
8. gata3-driven expression of miR-503 inhibits prostate cancer progression by repressing ZNF217 expression.
Jiang X; Chen Y; Du E; Yang K; Zhang Z; Qi S; Xu Y
Cell Signal; 2016 Sep; 28(9):1216-1224. PubMed ID: 27267060
[TBL] [Abstract] [Full Text] [Related]
9. Epithelioid Angiosarcoma of the Bladder: A Series of 9 Cases.
Matoso A; Epstein JI
Am J Surg Pathol; 2015 Oct; 39(10):1377-82. PubMed ID: 25929352
[TBL] [Abstract] [Full Text] [Related]
10. Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients.
Marina O; Gustafson GS; Kestin LL; Brabbins DS; Chen PY; Ye H; Martinez AA; Ghilezan MI; Wallace M; Krauss DJ
Brachytherapy; 2014; 13(1):59-67. PubMed ID: 23871661
[TBL] [Abstract] [Full Text] [Related]
11. Management of high-risk prostate cancer: radiation therapy and hormonal therapy.
Nomiya T; Tsuji H; Toyama S; Maruyama K; Nemoto K; Tsujii H; Kamada T
Cancer Treat Rev; 2013 Dec; 39(8):872-8. PubMed ID: 23648323
[TBL] [Abstract] [Full Text] [Related]
12. Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy.
Pinkawa M; Piroth MD; Holy R; Djukic V; Klotz J; Pfister D; Heidenreich A; Eble MJ
Radiat Oncol; 2012 Dec; 7():209. PubMed ID: 23227960
[TBL] [Abstract] [Full Text] [Related]
13. [Radiotherapy in the treatment of advanced and recurrent prostate cancer].
Böhmer D
Urologe A; 2012 Dec; 51(12):1759-69; quiz 1770-1. PubMed ID: 23150090
[TBL] [Abstract] [Full Text] [Related]
14. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract.
Gulmann C; Paner GP; Parakh RS; Hansel DE; Shen SS; Ro JY; Annaiah C; Lopez-Beltran A; Rao P; Arora K; Cho Y; Herrera-Hernandez L; Alsabeh R; Amin MB
Hum Pathol; 2013 Feb; 44(2):164-72. PubMed ID: 22995333
[TBL] [Abstract] [Full Text] [Related]
15. Challenge of dose escalation in locally advanced unfavourable prostate cancer using hdr brachytherapy.
Al-Salihi O; Mitra A; Payne H
Prostate Cancer Prostatic Dis; 2006; 9(4):370-3. PubMed ID: 16832383
[TBL] [Abstract] [Full Text] [Related]
16. [High-dose rate iridium-192 brachytherapy combined with external beam radiotherapy for localized prostate cancer].
Kasahara K; Inoue K; Karashima T; Inoue Y; Kariya S; Inomata T; Yoshida S; Shuin T
Nihon Hinyokika Gakkai Zasshi; 2001 Jul; 92(5):572-8. PubMed ID: 11517568
[TBL] [Abstract] [Full Text] [Related]
